Protective role of fish oil (Maxepa) on early events of rat mammary carcinogenesis by modulation of DNA-protein crosslinks, cell proliferation and p53 expression by Manna, Sangita et al.
BioMed Central
C
TIONALINTERNA
ANCER CELLCancer Cell International
ssOpen AccePrimary research
Protective role of fish oil (Maxepa) on early events of rat mammary 
carcinogenesis by modulation of DNA-protein crosslinks, cell 
proliferation and p53 expression
Sangita Manna1, Tridib Chakraborty1, Suresh Damodaran1, 
Kartick Samanta1, Basabi Rana2 and Malay Chatterjee*1
Address: 1Division of Biochemistry, Department of Pharmaceutical Technology, Jadavpur University, P.O. Box – 17028, Kolkata-700032, India 
and 2Cardiovascular and Cancer Research Institute, Texas A&M University System, Health Sciences Center, College of Medicine, Temple, TX-76504, 
USA
Email: Sangita Manna - sadaktumpa@yahoo.co.in; Tridib Chakraborty - chakraborty_t_ju@yahoo.com; 
Suresh Damodaran - tridib16@rediffmail.com; Kartick Samanta - m_chatterjee@lycos.com; Basabi Rana - brana@medicine.tamhsc.edu; 
Malay Chatterjee* - mcbiochem@yahoo.com
* Corresponding author    
Abstract
Background: Fish oil is known to protect from many types of cancers of the colon, liver, breast,
prostate and lung [1-3]. The objective of the present study was to evaluate the role of fish oil
[Maxepa, supplemented at a dose of 0.5 ml is equivalent to 90 mg eicosapentaenoic acid (EPA) and
60 mg docosahexaenoic acid (DHA)] on cell proliferation, expression of p53 tumor suppressor
protein and DNA protein crosslinks (DPCs) in a defined model of chemical rat mammary
carcinogenesis. Mammary carcinogenesis was initiated by a single, intravenous (i.v.) tail vein
injection of 7,12 dimethylbenz(α)anthracene (DMBA) at a dose of 5 mg DMBA/2 ml corn oil/kg
body weight in female Sprague-Dawley rats at 7 weeks of age. Fish oil supplementation was started
daily, 2 weeks prior to DMBA injection and continued for 24 (31 weeks of animal age) weeks and
35 (42 weeks of animal age) weeks of post DMBA injection, for histopathological and
immunohistochemical and for morphological studies, respectively.
Results: Our results indicate the chemopreventive effect of fish oil (Maxepa) on DMBA-induced
rat mammary carcinogenesis. Administration of fish oil further showed a prominent reduction of
cell proliferation (24.34%, P = 0.001); DPCs (25%, P < 0.001) and an increased expression of p53
protein (4.636 ± 0.19, P < 0.001) in preneoplastic mammary tissue when compared to carcinogen
control counterpart. Histopathological and morphological analyses were carried out as end-point
biomarkers.
Conclusion: Our study thus provides evidence for the anticarcinogenic effect of fish oil (Maxepa)
in limiting mammary preneoplasia in Sprague-Dawley rats.
Background
Emerging evidences from epidemiological and experi-
mental studies indicate a relationship between dietary fat
and the risk of cancer [1-4]. Especially it has been shown
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fatty acids have lower incidence of breast, prostate and
colon cancers than those who consume fewer amounts of
n-3 fatty acids (5). It is also reported that dietary fish oil
reduces the growth of subcutaneously transplanted
R3230AC mammary adenocarcinoma cells in female
F344 rats [6].
7,12 dimethylbenz(α)anthracene-(DMBA) induced
mammary carcinogenesis in rats has been widely used in
various mammary cancer chemopreventive studies [7,8].
This model appears to be most relevant to the develop-
ment of human breast cancer, especially in its origin. In
this model tumours appear from ductal epithelial cells as
in most human breast cancers. Moreover, histogenesis,
morphology and progression of hyperplastic premalig-
nant and malignant lesions are similar in many aspects to
those of human breast cancer [9].
Histopathology of a particular tissue is the basic marker
for the study of neoplasia. DNA-protein crosslinks (DPCs)
are proposed as indicators of early biological effects due to
carcinogen exposure [10,11]. The isolation of DPCs is
important not only for elucidation of functional and
structural aspects of DNA protein interactions but also
important for evaluation of genotoxicity of carcinogens.
DPC is a type of DNA damage that could be used as
biomarker for testing early carcinogenic exposure or early
lesions of carcinogenic process [12]. Cell proliferation can
influence carcinogenesis by a number of mechanisms
[13]. The p53 tumor suppressor gene product appears to
play a central role in carcinogenesis, and is integral in cell-
cycle control, DNA repair, cellular differentiation and
apoptosis [14]. The elevated expression of p53 can inhibit
cell proliferation.
In this present study, we have investigated the anticarcino-
genic role of fish oil (Maxepa) in a defined model of
chemical rat mammary carcinogenesis. This might throw
some light in understanding the role of these fatty acids in
the inhibition of mammary carcinogenesis.
Results
General observation
During the entire term of the study, no treatment related
alteration in the daily intake of food and drinking water
was observed among the different groups of rats. No dif-
ference in behavior patterns like irritability, aggressiveness
and apparent docility was noted.
Mammary histology
Figure 1, the normal control (group A) preserved normal
ductular and alveolar structure of mammary tissue with
epithelial cells of uniform appearance. Figure 2, mam-
mary tissue from DMBA-treated group (group B) showed
hyperplasia of the ductular cells characterized by multi-
layering and clustering of the cell with nuclear hyper chro-
masia and pleomorphism. The layering went up to more
than three cells and there were cellular bud formation in
some places. The cellular architecture was found to be
altered and enlargement of the alveolus was seen along
with cells showing nuclear enlargement, clumping of
chromatids and prominent nucleoli. It was observed from
histological examination that the DMBA + fish oil-treated
group (group C) presented a histological profile similar to
the normal control (Fig. 3). Tissue from this group (group
C) showed distinct reduction of hyperplasia as evidenced
by only normal double layer of cells with regular round
nuclei with presence of chromatin. The fish oil control
group (group D) showed no observable distinct change
from the normal control (figure not shown).
Morphological findings
The incidence (%) of palpable mammary tumours in the
DMBA control (group B) and fish oil-supplemented
DMBA group (group C) are shown in figure 4 and table 2.
In the DMBA control group, 90% of animals had tumours
at the end of 35 weeks (Table 2). The mean latency period
of tumour appearance was as early as 12.1 ± 0.3 weeks
post-carcinogen treatment. The mammary tumour usually
appeared one at a time with additional tumours appear-
ing even several weeks after the first tumour was observed.
The majority of tumours appeared between 15 and 25
weeks and multiple tumours of different sizes were fre-
quently found in the same animal. Most of the tumours
were between 2 and 5 mm3 in size (Table 2). Fish oil when
given to the carcinogen-treated animals (group C), its
inhibitory action could be ascertained from the reduced
tumour incidence (Fig. 4 and Table 2). In this group only
Histological section of mammary tissue of rats, showing nor-mal cellular arch tecture (Normal Control, group A)Figure 1
Histological section of mammary tissue of rats, showing nor-
mal cellular architecture (Normal Control, group A). Magnifi-
cation, H & E × 40.Page 2 of 10
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significantly different (P < 0.05) from group B (Table 2).
The mean latency period for tumour appearance for this
group was 15.7 ± 0.5 weeks post-carcinogen treatment,
which is significantly (P < 0.001) longer than group B.
From figure 4, it can be observed that there was a decrease
in the percentage of rats developing tumours with time in
the fish oil treated group. Between 25 and 31 weeks after
DMBA administration, significant (P < 0.001) lowering of
the percentage of rats developing tumours were observed
and again at a later stage (between 32 and 35 weeks), there
was a significant (P < 0.05) reduction in tumour-inci-
dence when compared to the carcinogen control group
(Fig. 4). Fish oil treatment also characteristically attenu-
ated the number of tumours of 2 and 5 mm3 in size indi-
cating slower tumour progression (Table 2).
Effect of Fish oil on induction of DPCs in vivo
DMBA-treated group results a clear demonstration of pro-
tein associated with DNA breaks. The carcinogen control
group exhibited an increase in DPC compared to their
normal counterparts (P < 0.001). Treatment with fish oil
(Maxepa) reduced the percentage of DPC by 25% (P <
0.001) when compared to carcinogen control counter-
parts. Thus, early changes during the carcinogenic process
were associated with increased percentage of DPC that
was reduced by treatment with fish oil (Fig. 5). Results
were analyzed by Student's t-test and one-way ANOVA (F
= 65535, F crit = 3.37, P < 0.001).
Cell proliferation
To analyze the chemopreventive action of fish oil
(Maxepa), we examined its effect on cellular proliferation
in the mammary gland. The percentage of BrdU-labelled
cells as calculated by LI (labeling index) was more in the
carcinogen control group B (Table 3). The BrdU-LI in the
DMBA control group (Group B) was 26.7 ± 2.54 and in
DMBA + fish oil group (Group C) was 20.2 ± 1.58. Thus,
there was substantial reduction in BrdU-LI by 24.34%, (P
= 0.001). The BrdU-labeled cells showed a distinct nuclear
localization. Figures 6 and 7 indicate representative pic-
tures of mammary tissue from the DMBA control group
Cumulative incidence of mammary tumours (adenocarcino-mas) in DMBA co trol (group B) as well as DMBA + M xep -tr ated (group C) groups on and from 10 weeks upto 35 w eksFigure 4
Cumulative incidence of mammary tumours (adenocarcino-
mas) in DMBA control (group B) as well as DMBA + 
Maxepa-treated (group C) groups on and from 10 weeks 
upto 35 weeks. P < 0.05 when compared to the DMBA con-
trol (group B) by Fisher's exact probability test.
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Histological section of mammary tissue of rats, showing marked prolif ration of ductal epi helial lining with hyper-chromat  enla ged nuclei (DMBA Control, group B) (marked with arr ws)Figur 2
Histological section of mammary tissue of rats, showing 
marked proliferation of ductal epithelial lining with hyper-
chromatic enlarged nuclei (DMBA Control, group B) 
(marked with arrows). Magnification, H & E × 40.
Histological section of mammary tissue of rats, showing almost normal cellular architecture with no sign  of prolifera-tion (DMBA + Maxepa Treatmen , group C)Figure 3
Histological section of mammary tissue of rats, showing 
almost normal cellular architecture with no signs of prolifera-
tion (DMBA + Maxepa Treatment, group C). Magnification, 
H & E × 40.Page 3 of 10
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C), respectively.
p53 immunoexpression
A few p53 immuno-positive cells (1.484 ± 0.021) was
detected in the mammary tissue sections of the carcinogen
control group (group B) (Fig. 8) when compared to group
A; whereas figure 9 showed an increase in p53 immunop-
ositivity (4.636 ± 0.19, P < 0.001) upon fish oil supple-
mentation (group C) when compared to DMBA control
(group B). p53 expression in the normal control (group
A) and Maxepa control (group D) were 8.456 ± 0.17 and
8.47 ± 0.16, respectively when compared to group B. One-
way ANOVA showed significant changes in p53 expres-
sion among various groups of animals (F = 65535, F crit =
3.37, P < 0.001).
Discussion
The present study highlights that fish oil (Maxepa) offers
considerable protection against DMBA-induced mam-
mary carcinogenesis in female Sprague-Dawley rats. Expo-
sure to DMBA resulted in hyperplasia that was reverted
almost near to normal following treatment with fish oil,
as evidenced by detailed histopathological analysis, indi-
cating the apparent chemopreventive potential of this oil.
As there is a close relationship between hyperplasia and
the subsequent steps leading to malignancy, the protective
role of fish oil against mammary carcinogenesis may be
manifested by gradual slowing of the occurrence of hyper-
plasia to a considerable extent and thereby delaying the
appearance of tumour with the increased latency period
[15,16].
Essential fatty acids are required for the normal structure
of the membranes including cell membranes, mitochon-
drial membranes and nuclear membranes. They are the
precursors of a whole series of second messengers [17]
thereby regulating of the formation of cytokines, and
modulate the behavior of most membrane bound pro-
teins including receptors, ion channels and ATPase [18].
n-3 fatty acids may be found in vegetable oils, especially
canola and soybean oil, and in green leafy vegetables as α-
linolenic acid (LNA) [18:3 (n-3)] and in larger amounts in
fatty cold water fish as eicosapentaenoic acid (EPA) [20:5
(n-3)] or docosahexaenoic acid (DHA) [22:6 (n-3)] [5]. n-
3 PUFA predominate in chloroplasts of green plants (lino-
lenic acid) and in phytoplanktons (EPA and DHA). Via
the marine food chain, all forms of marine life become
enriched with PUFA of the n-3 family [19].
An inhibitory role of fish oil was clearly indicated by the
reduced incidence of DMBA induced mammary tumours
in rats. An observation that a significant percentage of rats
Effect of fish oil on the percentage of DNA-protein crosslinks (DPCs) in mammary tissueFigure 5
Effect of fish oil on the percentage of DNA-protein crosslinks 
(DPCs) in mammary tissue. Each column and bar represents 
Mean ± SEM. P < 0.001 when DMBA control (group B) is 
compared to normal control (group A). P < 0.001 when 
DMBA + Maxepa treated group (group C) is compared to 
DMBA control (group B). P < 0.001 when DMBA control 
(group B) is compared to Maxepa control (group C).
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Table 2: Effect of fish oil on DMBA-induced palpable mammary tumors in rats after 35 weeks
Group No. of rats with 
tumorsa per total 
rats
Tumor incidence 
(%)
Total no. of tumors Tumor Size  (mm3)
<2 >2–<5
B 9/10 90 61 22 39
C 6/10 60b 32c 11 21
aPalpable tumors confirmed as adenocarcinomas by histopathology.
bSignificantly different from group B by Fischer's exact probability test (P < 0.05).
cSignificantly different from group B by Student's t-test (P < 0.01).Page 4 of 10
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can be explained by assuming the carcinogenic effect,
even if initiated, was suppressed to a considerable extent
as indicated by a long latency period of tumour develop-
ment [20]. The observed beneficial effect of fish oil on
tumour growth as evidenced by the reduced tumour size
may represent a selective toxicity to proliferative cells.
DPCs are shown to induce by many carcinogens [11].
DNAs may result in large deletions during DNA replica-
tion, possibly leading to the interaction or loss of DNA
sequences that may be important for tumour suppression
[21]. It has been previously reported by us that DNA pro-
tein crosslinks that occurs during experimental rat hepato-
carcinogenesis, was substantially reduced by
chemopreventive agent vanadium [22]. In vitro studies by
Ducore further revealed the presence of DNAs in the
murine leukemia cell line L1210 that were removed in the
presence of theophylline [23]. Thus fish oil-mediated
reduction of DPCs clearly demonstrates the promising
inhibitory effect of fish oil to an appreciable extent in
mammary carcinogenesis.
Cell proliferation is a fundamental process integral to car-
cinogenesis. It is considered to play an important role in
several steps of carcinogenic process: initiation, promo-
tion and progression. There are multitudes of factors
known to regulate cell proliferation in breast cancer. It
was found by Ip et al that selenium substantially reduced
cell proliferation during mammary preneoplasia in exper-
imental animals [24]. Again, it was also shown by Shah et
al that reduction of cell proliferation of breast cancer cell
line SKBR3 occurred upon treatment with retinoic acid
[25]. Our results of cell proliferation studies did show a
significant reduction of proliferating preneoplastic cells in
the mammary tissue upon fish oil supplementation.
The most common anti-apoptotic lesion that is detected
in cancers is the inactivation of the p53 tumour-suppres-
sor pathway. p53 is evolved in higher organisms to pre-
vent tumour development. Several responses can be
provoked by p53, including cell-cycle arrest, senescence,
differentiation and apoptosis, with the option chosen
being dependent on many factors that are both intrinsic
and extrinsic to the cell. In most cases, induction of p53
Representative immunohistochemistry photomicrograph of BrdU-labeling of rat mammary tissue [DMBA + Maxepa-tr at d group (group C)]Figure 7
Representative immunohistochemistry photomicrograph of 
BrdU-labeling of rat mammary tissue [DMBA + Maxepa-
treated group (group C)]. Arrows (→) indicate BrdU-
labelled brown-stained cells. Magnification, × 40.
Table 3: BrdU-LI in mammary tissue
Groups Brdu-LIa
Group B (DMBA control) 26.7 ± 2.54b
Group C (DMBA + Maxepa) 20.2 ± 1.58
LI = labeling index
BrdU-LI = percentage of BrdU-labeled cell/total number of cells counted.
aApproximately 200 cells were counted per field, 10 fields were examined per slide and 10 slides were examined per group.
bValues represents mean ± SEM.
Representative immunohistochemistry photomicrograph of BrdU-labeling of rat mammary tissue [DMBA Control (group )]Figure 6
Representative immunohistochemistry photomicrograph of 
BrdU-labeling of rat mammary tissue [DMBA Control (group 
B)]. Arrows (→) indicate BrdU-labelled brown-stained cells. 
Magnification, × 40.Page 5 of 10
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decisively by activating apoptosis [26]. Studies by Srivas-
tava et al have shown that there was elevation of p53
expression during the inhibition of experimental mam-
mary carcinomas by human chorionic gonadotropin
(hCG) treatment [27]. It was also evidenced by Kim et al
that chloroform extract of Caesalpinia sappan, increased
the expression of p53 in head and neck cancer cells in vitro
[28]. It can be mentioned that the inhibition of mammary
preneoplasia may be mediated through the elevated
expression of p53 gene. The decrease in the expression of
p53 shows a parallel decrease in C-Myc and IL-Iβ-convert-
ing enzyme. Maxepa treatment showed an elevation in the
expression of p53 in parallel with C-Myc and ICE genes
when compared to carcinogen control group. This ele-
vated expression was maintained for at least 15 days. This
increase is also followed by significant elevations of C-
Myc and p53 mRNAs. Though p53 is the most common
mutated genes in human cancers, development of malig-
nancies retain the wild-type p53 gene that is associated
with its reduced activity due to overexpression of MdM2
and other cellular factors that down-regulate its level (29).
Therefore, a substantial effort is presently focused on
developing p53 functions in tumours harboring repressed
wild-type p53.
Conclusion
The involvement of fish oil (Maxepa) in suppressing neo-
plastic transformation of mammary tissue might be medi-
ated through the decrease of DPCs, cell proliferation and
elevation of p53 tumour suppressor protein leading to
apoptosis. However, its exact molecular action in combat-
ing mammary carcinogenesis requires further study. The
activation of p53 by fish oil (29) may appear therefore to
be a promising effective approach for the prevention of
mammary tumour development.
Methods
Animals and treatment
Inbred virgin female Sprague-Dawley rats obtained from
Indian Institute of Chemical Biology, CSIR, (Kolkata,
India) were used for the experiments. Animals of 20 ± 2
days (3 weeks) old were housed in animal cages (Tarsons)
in a room, which was maintained temperature (25 ± 1°C)
and humidity (50–60%) and exposed to a 12:12 hour
light and dark cycle. All rats were fed a normal diet (5%
mixed fat) (Ralston Purina Co., St. Louis, Mo) [6], [Table
1] and de-mineralized drinking water ad libitum. The rats
were acclimatized to the laboratory conditions for a
period of 2 weeks before the start of the experiment. The
recommendations of Jadavpur University's "Institutional
Animal Ethics Committee" ["Committee for the Purpose
of Control and Supervision of Experiments on Animals"
(CPCSEA Regn. No. 0367/01/C/CPCSEA) India] for the
care and use of laboratory animals were strictly followed
throughout the study.
The entire experiment consisted of two parts: (I) his-
topathological and immunohistochemical estimations
(II) morphological study of mammary tumors. For part
(I), a total of 80 animals were divided into four groups,
denoted as A, B, C and D. For histological and immuno-
histochemical studies (part I) twenty animals from each
group (4 rats/cage) were used. At 7 weeks of age animals
of group B and C were given a single, i.v. tail vein DMBA
Immunolocalization of p53 in the mammary tissue of rats [DMBA + Maxepa-treated group (group C)] with anti-sheep p53 a tibody (1:200) and AECFigure 9
Immunolocalization of p53 in the mammary tissue of rats 
[DMBA + Maxepa-treated group (group C)] with anti-sheep 
p53 antibody (1:200) and AEC. Arrows (→) indicate p53 
immuno-positive cells in mammary tissue of rats. Magnifica-
tion, × 40.
Immunolocalization of p53 in the mammary tissue of rats [DMBA Control (gr u  B)] with anti-sheep p53 antibody(1:200) and AECFigure 8
Immunolocalization of p53 in the mammary tissue of rats 
[DMBA Control (group B)] with anti-sheep p53 antibody 
(1:200) and AEC. Arrows (→) indicate p53 immuno-positive 
cells in mammary tissue of rats. Magnification, × 40.Page 6 of 10
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weight in female Sprague-Dawley rats [30]. Since, 0.2 ml
of the oil was injected; the concentration of DMBA in the
corn oil was 0.5 mg DMBA/0.2 ml corn oil/100 g body
weight. For the morphological study (part II), a total of
250 rats were assigned to the carcinogen control group
(i.e. group B) and another 250 were assigned to the DMBA
+ fish oil-treated group (i.e. group C). Ten animals from
each group (i.e. group B and C) were sacrificed each week
starting 10 weeks (17-weeks of animal age) after the
DMBA injection and continued to 35 weeks (42 weeks of
animal age). The treatments for various groups were as
follows:
Group A
Normal control animal at 7 weeks of age were given a sin-
gle tail vein injection of 2 ml corn oil/kg body weight.
Group B
DMBA-administered animals served as the carcinogen
control.
Group C
DMBA + fish oil [Maxepa, (Maxepa® as manufactured by
Merck Limited, Goa, India) supplemented at a dose of 0.5
ml ≈ 90 mg eicosapentaenoic acid (EPA) and 60 mg
docosahexaenoic acid (DHA)] supplemented group. Each
rat was given fish oil (Maxepa) orally, 2 weeks (5 weeks of
animal age) prior to DMBA injection, via an intragastric
tube according to Karmali et al [6].
Group D
Served as the fish oil (Maxepa) control.
Fish oil supplementation was started 2 weeks (5 weeks of
animal age) prior to DMBA administration and continued
until the termination of the experiments. The dose was
given once daily, for 24 (31 weeks of animal age) weeks
for histopathological and immunohistochemical analysis
and 35 (42 weeks of animal age) weeks for morphological
study. Fatty acid composition in the oil was determined
by gas-liquid chromatography (GLC). The samples were
eluted on a capillary BD23 column (J&W Scientific) after
saponification with sodium hydroxide in methanol and
transmethylation of the fatty acids with boron-trifluoridfe
in methanol [31]. Food and liquid consumption were
monitored daily by subtracting from what was provided
anything not consumed by 08:00 hours the next day, from
which, the approximate food and liquid consumptions
were calculated per day per rat. Close monitoring of the
individual rat with marking in the tail was made. The
body weight also was recorded weekly throughout the
experiment and as such, there was a continuous monitor-
ing of food and water intakes of the individual rat during
the course of experiment. The animals were palpated
twice a week to check for the development of palpable
mammary tumours and the time of tumour appearance
was also recorded.
Histological evaluation of mammary tissue
Twenty-four (31 weeks of animal age) weeks after the car-
cinogen or vehicle treatment, animals from each group
were randomly selected; the thoracic and abdominal
inguinal mammary tissues were excised from ether-anes-
thetized rats, fixed in 10% formalin and processed for his-
tological studies. The tissues were dehydrated through 70,
90 and 100% alcohol and embedded in low melting-
point paraffin wax. Sections of 5 μm thickness were cut
and placed serially on glass slides. The sections were
deparaffinized in xylene and rehydrated through 100, 90
and 70% alcohol. Three contiguous sections were made
from each mammary tissue and stained with hematoxylin
and eosin for histological evaluation using light micros-
copy. The histological slides were coded so that the partic-
ular sample identity was unknown to the individual
making the assessment.
Morphological study
Ten animals from each group were sacrificed each week
starting 10 (17 weeks of animal age) weeks after the
DMBA injection and continuing for up to 35 (42 weeks of
animal age) weeks. The animals were anesthetized with
ether and opened by a midline incision from the pubis to
the submaxillary area. The skin was dissected to expose six
Table 1: Diet Composition
Ingredient Amount
Mixed Fat 5%
Casein (g) 17.10
DL-Methionine (g) 0.30
Dextrine (g) 45.50
Sucrose (g) 22.70
AIN-salt mixture (g) 3.50
AIN-vitamins (g) 1.00
Cellulose (g) 5.00
The calculated energy value (metabolizable energy) for the diet is 3.87 K.cal/g.Page 7 of 10
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mammary fat pad by vascularization or presence of any
palpable as well as non-palpable tumours was recorded.
Only well-developed adenocarcinomas, confirmed
through histology according to the criteria of Young and
Hallows [32], is reported in the Results section. Tumour
size was calculated using the formula for the volume of a
prolate spheroid: volume = 4/3 × 3.14 × (length/2) ×
(width/2) × (depth/2). The width measurement was used
as the depth of the tumor [33]. The diameter measure-
ments were further made by using a calipers and the vol-
ume of the tumor was calculated from the diameter using
a stereoscopic microscope equipped with an intraocular
reticule [34]. Mammary gland was exposed for the detec-
tion of non palpable tumors only at autopsy.
Isolation of DPCs
DNA-protein complex (DPCs) from cells was isolated
with slight modifications as described by Zhitkovich and
Costa [11] and reported previously from our laboratory
[22]. A bovine serum albumin was taken as standard
blank. The DPC-coefficient was determined as a ratio of
the percentage of SDS precipitable DNA in treated sample
to the percentage of SDS precipitable DNA in untreated
control sample. Fluorescent measurements were made
using model LS45 luminescence spectrometer (Perkin
Elmer, UK) with NB 360 excitation and SC 450 emission
filters. For protein estimation, the isolated DPCs were
nuclease-digested for 1 h at 37°C; protein was estimated
according to Lowry et al. [35].
Cell proliferation assay by immunostaining with 5'-bromo-
2-deoxyuridine (BrdU)
At 6 hours before sacrifice ten animals from each group
were given i.p. injections of BrdU at a dose of 50 mg/kg
body weight. Only the rats in diestrus phase were used as
a standard protocol. The diestrus phase was determined
by histological examination of vaginal smears. The ani-
mals were anesthetized with ether and mammary tissues
were dissected out. Immunohistochemical staining was
done according to Zhu et al [36]. Briefly, tissue sections
were exposed to 0.3% hydrogen peroxide in ethanol for
10 min to block endogenous peroxidase and treated with
2N HCl for 1 h and incubated with trypsin 0.1% for 20
min and then with normal goat serum for 20 min at room
temperature. After tissue sections were incubated with the
primary antibody at room temperature (anti-BrdU mouse
monoclonal antibody, Sigma) in a humid chamber
(1:125 for 2 h) and then with biotinylated anti-mouse IgG
(1:200; Sigma) and then with streptavidin horse radish
peroxidase which binds to biotin with washing in PBS
after each incubation. Visualization was revealed by reac-
tion with 3,3'diaminobenzidine (DAB; Sigma) and 0.04%
hydrogen peroxide. All slides were counterstained with
hematoxylin, rinsed, dehydrated and mounted with per
mount. Dark brown stains identify the cells incorporating
the BrdU-label. Approximately 200 cells were counted per
field, 10 fields were examined per slide and 10 slides were
examined per group. The labeling index (LI) was calcu-
lated as % of BrdU positive nuclei per total number of
cells counted.
Immunostaining of p53
Immunohistochemical detection of p53 protein in cold
acetone fixed, paraffin embedded mammary sections was
performed by the avidin-biotin-peroxidase-complex
method [37]. Briefly 5 μM thin sections on lysine-coated
slides were deparaffinized and rehydrated. For immunola-
beling of p53, antigen retrieval was facilitated by heating
the sections in citrate buffer (pH 6.0) for 20 min. Then
Endogenous peroxidase activity was blocked with 1%
H2O2 in 0.1 M Tris-Nacl (PH-7.6) for 30 mins. After incu-
bation in 5% normal goat serum sections were then sepa-
rately incubated overnight at 4°C with the primary
antibody, anti-sheep p53 antibody (Sigma) at 1:200 dilu-
tion in 1% BSA. Sections were then incubated with a bioti-
nylated secondary antibody goat antirabbit IgG (Sigma)
for 30 mins at 37°C with 1:100 dilutions. This was fol-
lowed by incubation with streptavidin peroxidase (1:100)
for 1 hour and subsequent chromagen development with
3-amino 9 ethyl carbazole (AEC-H2O2 solution) (AEC-10
mg, N, N dimethyl formamide-2.5 ml, 0.1 N acetate
buffer-47.5 ml, 3% H2O2-0.5 ml.) for 4–5 min. The sec-
tions were then counterstained with Harris hematoxylin,
dehydrated and mounted and served as positive control.
Negative controls were prepared following all the above-
mentioned steps omitting the primary antibody. Approx-
imately 200 cells were counted per field, 10 fields were
examined per slide and 10 slides were examined per
group.
Statistical analysis
Comparison of the incidence of mammary tumour in dif-
ferent experimental groups was carried out using Fischer's
exact probability test. Average standard deviation and
standard error were calculated. Statistical analyses were
performed using One Way ANOVA for multiple compari-
sons, with the level of significance set at 5%. Data were
further analyzed using Student's t-test. The criteria of sig-
nificance were taken as P < 0.05.
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